Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

13.02 +0.22 (+1.72%)
Official Closing Price Updated: 4:15 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading. 
Via Benzinga
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Where Enanta Pharmaceuticals Stands With Analysts ↗
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial ↗
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has dosed the first subject in its Phase 1 trial of EDP-235, a coronavirus 3CL protease inhibitor, specifically designed as a... 
Via Benzinga
News headline image
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes ↗
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
News headline image
Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals: Q1 Earnings Insights ↗
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q1 earnings results on Tuesday, February 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
What 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals ↗
Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
Earnings Scheduled For February 8, 2022 ↗
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Thursday ↗
RBC Capital boosted KB Home (NYSE: KBH) price target from $46 to $55. KB Home shares rose 6.7% to $45.20 in pre-market trading. Cowen & Co. reduced the price target on... 
Via Benzinga
News headline image
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
Enanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
7 A-Rated Biotechs to Buy for the Long Run ↗
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples. 
Via InvestorPlace
News headline image
Where Enanta Pharmaceuticals Stands With Analysts ↗
Over the past 3 months, 11 analysts have published their opinion on Enanta Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
56 Biggest Movers From Yesterday ↗
Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating... 
Via Benzinga
News headline image
Enanta Pharmaceuticals, inc (ENTA) Q4 2021 Earnings Call Transcript ↗
ENTA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
News headline image
52 Biggest Movers From Friday ↗
Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland Technologies highlighted the launch of second... 
Via Benzinga
News headline image
Earnings Scheduled For November 22, 2021 ↗
Companies Reporting Before The Bell • Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per share on revenue of $97.92 million. • Avaya... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares... 
Via Benzinga
News headline image
Enanta Pharmaceuticals's Earnings: A Preview ↗
Enanta Pharmaceuticals (NASDAQ:ENTA) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.